The company, which today announced plans to sell 50 per cent stake in joint venture Schutz Dishman for three lakh euros to its promoters, had reported a consolidated net profit of Rs 38.61 crore in January-March period of 2014-15.
Net sales declined 3.55 per cent to Rs 405.67 crore in the quarter as against Rs 420.62 crore a year ago, Dishman Pharmaceuticals and Chemicals said in a BSE filing.
For the full fiscal, net profit rose 42.83 per cent to Rs 171.12 crore compared with Rs 119.81 crore in the previous fiscal, it said.
The company said the board also approved selling of investment made by the company in Schutz Dishman Biotech to its promoters.
Also Read
Post the acquisition, the company's holding in the JV went up to 72.33 per cent from 22.33 per cent. However, the JV posted a net loss of Rs 1.13 crore and sales of Rs 2.93 crore in the quarter ended March.
"Since Schutz Dishman is incurring losses and which may impact on the net worth of the Dishman going forward and since the turnaround of Schutz Dishman may take some time, the board of directors of the company has decided to sale the additional stake (7.5 lakh equity shares) to the promoters of the company," the company said.
The sale will be at a consideration of Rs 30 per share, which is the same price at which Dishman had acquired the stake from Schutz & Co, it said, adding that after the sale, the company's stake in Schutz Dishman shall be 22.33 per cent.